ASCO 2024 Dark Matter Interview with Dr. Bernard Fox American Society of Clinical Oncology, Dark Matter Interview, ASCO. June 1, 2024
An Off-the-Shelf Multivalent Vaccine Containing Cancer’s Dark Matter, DPV-001, Combined with PD-1 +/- GITR in Head & Neck Cancer: Safety, Efficacy, and Immunodynamics from the Phase 1 GITRVax Trial. These data will be presented by Rom S. Leidner, M.D., during the First-in-Human Phase I Clinical Trials Session 1 on April 8 (No. CT112, Poster Section 48, 1:30 to 5pm), at the American Association for Cancer Research Annual Meeting held 5-10 April in San Diego, CA. https://www.einpresswire.com/article/701519390/dpv-001-vaccine-containing-cancer-s-dark-matter-yields-2-to-3-fold-increased-response-rate-for-head-and-neck-cancer